[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547350":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":56,"centralContacts":60,"locations":64,"responsibleParty":70,"collaborators":64,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":64,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":64,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":97,"whyStopped":64,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":64},{"fullName":5,"class":6},"Beijing Tiantan Hospital","OTHER",[8,15,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Local analgesic techniques + dexmedetomidine group","EXPERIMENTAL","The patients in this group will be received scalp nerve block before surgery with 0.67 % liposomal bupivacaine. The patients also will be given dexmedetomidine intravenously at a rate of 0.4 μg\u002Fkg\u002Fh from skin incision until the beginning of dura mater closure, and will be adjusted to 0.05 μg\u002Fkg\u002Fh for 48 hours after surgery.",[13,14],"Drug: Dexmedetomidine","Other: Local analgesic techniques",{"label":16,"type":10,"description":17,"interventionNames":18},"Local analgesic techniques and placebo dexmedetomidine group","The patients in this group will be received scalp nerve block before surgery with 0.67 % liposomal bupivacaine. For dexmedetomidine placebo group, normal saline will be infused at the same rate as dexmedetomidine during surgery and for 48 hours after surgery.",[19,14],"Drug: Normal saline",{"label":21,"type":10,"description":22,"interventionNames":23},"Placebo local analgesic techniques and dexmedetomidine group","The patients in this group will not receive scalp nerve block. The patients will be given dexmedetomidine intravenously at a rate of 0.4 μg\u002Fkg\u002Fh from skin incision until the beginning of dura mater closure, and will be adjusted to 0.05 μg\u002Fkg\u002Fh for 48 hours after surgery.",[13,24],"Other: no Local analgesic techniques",{"label":26,"type":27,"description":28,"interventionNames":29},"Placebo local analgesic techniques and placebo dexmedetomidine group","PLACEBO_COMPARATOR","The patients in this group will not receive scalp nerve block before surgery . For dexmedetomidine placebo group, normal saline will be infused at the same rate as dexmedetomidine group during surgery and for 48 hours after surgery.",[19,24],[31,38,44,50],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","Dexmedetomidine","The 200ug dexmedetomidine will be diluted into a 50ml syringe and administered with 0.4ug\u002Fkg\u002Fh intraoperatively and 0.05 μg\u002Fkg\u002Fh for 48 hours after surgery.",[9,21],[37],"DEX",{"type":32,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Normal saline","In the placebo group, the 0.9% saline is administered with the same volume at the same speed as the dexmedetomidine group",[16,26],[43],"NS",{"type":6,"name":45,"description":46,"armGroupLabels":47,"otherNames":48},"Local analgesic techniques","As for scalp nerve block, each nerve will be blocked separately with 1-2 mL of 0.67 % liposomal bupivacaine",[9,16],[49],"LAT",{"type":6,"name":51,"description":52,"armGroupLabels":53,"otherNames":54},"no Local analgesic techniques","No Local analgesic techniques will be given.",[21,26],[55],"NLAT",[57],{"name":58,"affiliation":5,"role":59},"Yuming Peng, Dr","PRINCIPAL_INVESTIGATOR",[61,66],{"name":58,"role":62,"phone":63,"phoneExt":64,"email":65},"CONTACT","8610-59976658",null,"florapym766@163.com",{"name":67,"role":62,"phone":68,"phoneExt":64,"email":69},"Min Zeng, Dr","15810617027","fly800727@163.com",{"type":59,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":64,"oldOrganization":64},"Yuming Peng","Deputy chief of Department of Anesthesiology","100547350","perioperative-multimodal-analgesia-protocol-for-supratentorial-craniotomy-100547350",false,"NCT06406829","Perioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy","Perioperative Multimodal Analgesia Protocol for Supratentorial Craniotomy：a 2× 2 Factorial Randomized Clinical Trial","Inclusion Criteria:\n\n* Aged from 18 to 65 years\n* American Society of Anesthesiologists physical status I to III\n* Scheduled to undergo elective supratentorial tumor resection\n\nExclusion Criteria:\n\n* Incision-area skin infection\n* A history of previous craniotomy\n* Allergy to study medications\n* A history of preoperative change in consciousness or cognitive function\n* Severe hepatic or renal dysfunction\n* Severe bradycardia (heart rate\\\u003C40 beats\u002Fmin)\n* Sick sinus syndrome or second- to-third degree atrioventricular block","ALL","18 Years","65 Years",{"count":84,"type":85},2000,"ESTIMATED","INTERVENTIONAL",[88],"NA","Supratentorial craniotomy is one of the most common neurosurgical procedures, with severe perioperative pain. Inadequate perioperative pain relief has been associated with increased blood pressure and intracranial pressure, favoring bleeding and cerebral cerebral hypoperfusion. The ideal analgesia for neurosurgery requires complete pain relief, eliminates the side effects of opioid drugs and no influence for neurological function. Previous studies have proposed a multimodal analgesic strategy, combining analgesics and local anaesthesia, it is expected to achieve the above benefits.",[91,92,93],"Postoperative Pain","Analgesia","Supratentorial Brain Tumor",[95,96],"multimodal analgesia","Postoperative acute pain","NOT_YET_RECRUITING","2026-02-08",{"date":100,"type":101},"2026-02-11","ACTUAL",{"date":103,"type":85},"2026-02-09",{"date":105,"type":85},"2027-12-31",{"name":5,"class":6}]